RENEW
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 225 patients (estimated)
- Sponsors
- Keros Therapeutics, Inc.
- Collaborators
- PSI CRO
- Tags
- Activin Receptor IIA Inhibitor, Closed Label (Masked), Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2037
- NCT Identifier
- NCT06499285
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.